Value of baseline PSA in predicting prostate cancer diagnosis and death. Spanish arm of the European Randomized Study of Screening for Prostate Cancer

Introduction Several studies have suggested that prostate-specific antigen (PSA) in young men may predict the risk of developing prostate cancer (PC). Our aim is to study baseline PSA as a prognostic factor in the lifetime risk of developing PC, clinically significant PC (csPC), and metastatic PC (m...

Descripción completa

Detalles Bibliográficos
Autores: García-Cano-fernández, Alba María, Borda, Álvaro Páez, González, Luis Llanes, Galán, Marcos Luján
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universidad Francisco de Vitoria
Repositorio:DDFV. Repositorio Institucional de la Universidad Francisco de Vitoria
Idioma:inglés
OAI Identifier:oai:ddfv.ufv.es:10641/7620
Acceso en línea:https://hdl.handle.net/10641/7620
Access Level:acceso abierto
Palabra clave:prostate cancer ‹› baseline PSA ‹› prostate cancer death ‹› clinically significant prostate cancer ‹› metastatic prostate cancer
Urology
SDG 3 - Good Health and Well-being
Journal Article
Yes
yes
id ES_f3198a1b44a5df573faabfb8a395e158
oai_identifier_str oai:ddfv.ufv.es:10641/7620
network_acronym_str ES
network_name_str España
repository_id_str
spelling Value of baseline PSA in predicting prostate cancer diagnosis and death. Spanish arm of the European Randomized Study of Screening for Prostate CancerGarcía-Cano-fernández, Alba MaríaBorda, Álvaro PáezGonzález, Luis LlanesGalán, Marcos Lujánprostate cancer ‹› baseline PSA ‹› prostate cancer death ‹› clinically significant prostate cancer ‹› metastatic prostate cancerUrologySDG 3 - Good Health and Well-beingJournal ArticleYesyesIntroduction Several studies have suggested that prostate-specific antigen (PSA) in young men may predict the risk of developing prostate cancer (PC). Our aim is to study baseline PSA as a prognostic factor in the lifetime risk of developing PC, clinically significant PC (csPC), and metastatic PC (mPC), as well as to assess its impact on long-term mortality. Material and methods This study was a retrospective analysis involving 2,415 men aged 45–70 years, all participants in the Spanish arm of the European Randomized Study of Screening for Prostate Cancer (ERSPC). These men underwent PSA testing, and prostate biopsies were performed if their PSA levels were ≥3 ng/ml. The follow-up period spanned from September 2, 1996, to February 11, 2021. Kaplan-Meier survival analysis was conducted to calculate the probability of prostate cancer diagnosis and death. The relationship between these probabilities and baseline PSA levels was assessed using the log-rank test. Results After 25 years of follow-up, the probability of being free of a diagnosis of PC was 95.5%, 89.6%, 80.0%, and 69.4%; and of PC death: 99.6%, 99.6%, 98.9%, and 98.3% for the categories of PSA <1 ng/ml, 1–1.9 ng/ml, 2–2.9 ng/ml, and >3 ng/ml, respectively. There is an association between baseline PSA level and the probability of PC diagnosis (which is maintained in age stratification), csPC, mPC (p <0.001), and PC death (p = 0.047). Conclusions There is a clear relationship between baseline PSA and the probability of detection of PC, csPC and mPC during follow-up, as well as PC death, in a cohort belonging to the Spanish branch of the ERSPC, with a median follow-up of more than 23 years. Baseline PSA level can be used to define the most appropriate PC screening interval for everyone.Facultad de Medicina20242024-01-0120242024-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10641/7620reponame:DDFV. Repositorio Institucional de la Universidad Francisco de Vitoriainstname:Universidad Francisco de VitoriaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:ddfv.ufv.es:10641/76202026-06-11T12:44:57Z
dc.title.none.fl_str_mv Value of baseline PSA in predicting prostate cancer diagnosis and death. Spanish arm of the European Randomized Study of Screening for Prostate Cancer
title Value of baseline PSA in predicting prostate cancer diagnosis and death. Spanish arm of the European Randomized Study of Screening for Prostate Cancer
spellingShingle Value of baseline PSA in predicting prostate cancer diagnosis and death. Spanish arm of the European Randomized Study of Screening for Prostate Cancer
García-Cano-fernández, Alba María
prostate cancer ‹› baseline PSA ‹› prostate cancer death ‹› clinically significant prostate cancer ‹› metastatic prostate cancer
Urology
SDG 3 - Good Health and Well-being
Journal Article
Yes
yes
title_short Value of baseline PSA in predicting prostate cancer diagnosis and death. Spanish arm of the European Randomized Study of Screening for Prostate Cancer
title_full Value of baseline PSA in predicting prostate cancer diagnosis and death. Spanish arm of the European Randomized Study of Screening for Prostate Cancer
title_fullStr Value of baseline PSA in predicting prostate cancer diagnosis and death. Spanish arm of the European Randomized Study of Screening for Prostate Cancer
title_full_unstemmed Value of baseline PSA in predicting prostate cancer diagnosis and death. Spanish arm of the European Randomized Study of Screening for Prostate Cancer
title_sort Value of baseline PSA in predicting prostate cancer diagnosis and death. Spanish arm of the European Randomized Study of Screening for Prostate Cancer
dc.creator.none.fl_str_mv García-Cano-fernández, Alba María
Borda, Álvaro Páez
González, Luis Llanes
Galán, Marcos Luján
author García-Cano-fernández, Alba María
author_facet García-Cano-fernández, Alba María
Borda, Álvaro Páez
González, Luis Llanes
Galán, Marcos Luján
author_role author
author2 Borda, Álvaro Páez
González, Luis Llanes
Galán, Marcos Luján
author2_role author
author
author
dc.contributor.none.fl_str_mv Facultad de Medicina
dc.subject.none.fl_str_mv prostate cancer ‹› baseline PSA ‹› prostate cancer death ‹› clinically significant prostate cancer ‹› metastatic prostate cancer
Urology
SDG 3 - Good Health and Well-being
Journal Article
Yes
yes
topic prostate cancer ‹› baseline PSA ‹› prostate cancer death ‹› clinically significant prostate cancer ‹› metastatic prostate cancer
Urology
SDG 3 - Good Health and Well-being
Journal Article
Yes
yes
description Introduction Several studies have suggested that prostate-specific antigen (PSA) in young men may predict the risk of developing prostate cancer (PC). Our aim is to study baseline PSA as a prognostic factor in the lifetime risk of developing PC, clinically significant PC (csPC), and metastatic PC (mPC), as well as to assess its impact on long-term mortality. Material and methods This study was a retrospective analysis involving 2,415 men aged 45–70 years, all participants in the Spanish arm of the European Randomized Study of Screening for Prostate Cancer (ERSPC). These men underwent PSA testing, and prostate biopsies were performed if their PSA levels were ≥3 ng/ml. The follow-up period spanned from September 2, 1996, to February 11, 2021. Kaplan-Meier survival analysis was conducted to calculate the probability of prostate cancer diagnosis and death. The relationship between these probabilities and baseline PSA levels was assessed using the log-rank test. Results After 25 years of follow-up, the probability of being free of a diagnosis of PC was 95.5%, 89.6%, 80.0%, and 69.4%; and of PC death: 99.6%, 99.6%, 98.9%, and 98.3% for the categories of PSA <1 ng/ml, 1–1.9 ng/ml, 2–2.9 ng/ml, and >3 ng/ml, respectively. There is an association between baseline PSA level and the probability of PC diagnosis (which is maintained in age stratification), csPC, mPC (p <0.001), and PC death (p = 0.047). Conclusions There is a clear relationship between baseline PSA and the probability of detection of PC, csPC and mPC during follow-up, as well as PC death, in a cohort belonging to the Spanish branch of the ERSPC, with a median follow-up of more than 23 years. Baseline PSA level can be used to define the most appropriate PC screening interval for everyone.
publishDate 2024
dc.date.none.fl_str_mv 2024
2024-01-01
2024
2024-01-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/10641/7620
url https://hdl.handle.net/10641/7620
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2

http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2

http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:DDFV. Repositorio Institucional de la Universidad Francisco de Vitoria
instname:Universidad Francisco de Vitoria
instname_str Universidad Francisco de Vitoria
reponame_str DDFV. Repositorio Institucional de la Universidad Francisco de Vitoria
collection DDFV. Repositorio Institucional de la Universidad Francisco de Vitoria
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424345128894464
score 15,811543

Similares en LA Referencia